Evidence map›Paper›PMID 30941738›Full record

ArticlePathology oncology research : POR2020

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations.

Kornélia Kajáry, Zsolt Lengyel, Anna-Mária Tőkés, Janina Kulka, Magdolna Dank, Tímea Tőkés

Open access · hybridAbstract read
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Modelling image quality over extended [Frontiers in oncology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. KineticEJNMMI physics · 2024
    Article
  9. Article
  10. Evaluating the correlation between pretreatmentPathology oncology research : POR · 2024
    Article
  11. Quantitative parameters of static imaging and fast kinetics imaging inQuantitative imaging in medicine and surgery · 2023
    Article
  12. Value of DynamicMolecular imaging and radionuclide therapy · 2023
    Article
  13. Tumor infiltrating lymphocytes and radiological picture of the tumor.Medical oncology (Northwood, London, England) · 2023
    Review
  14. The Relationship between Pathological Features andWorld journal of nuclear medicine · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Correlation BetweenFrontiers in oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kornélia KajáryPozitron PET/CT Center, Hunyadi J. Str. 9, Budapest, H-1117, Hungary.
Zsolt LengyelPozitron PET/CT Center, Hunyadi J. Str. 9, Budapest, H-1117, Hungary.
Anna-Mária TőkésSemmelweis University 2nd Department of Pathology, Üllői str. 93., Budapest, H-1091, Hungary.
Janina KulkaSemmelweis University 2nd Department of Pathology, Üllői str. 93., Budapest, H-1091, Hungary.
Magdolna DankSemmelweis University Oncology Center, Tömő utca 25-29, 4th floor, Budapest, H-1083, Hungary.
Tímea TőkésSemmelweis University Oncology Center, Tömő utca 25-29, 4th floor, Budapest, H-1083, Hungary. tokes.timea@med.semmelweis-univ.hu.ORCID http://orcid.org/0000-0002-5456-1706
Semmelweis University · HUPozitron-Diagnosztika Kft · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type; nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients' informed consent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and assessed plasma activity noninvasively. To delineate primary tumors we applied a frame-by-frame semi-automatic software-based correction of motion artefacts. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate). We found that k3, Ki and MRFDG were significantly higher in higher grade (p = 0.0246, 0.0089 and 0.0076, respectively), progesterone-receptor negative (p = 0.0344, 0.0217 and 0.0132) and highly-proliferating (p = 0.0414, 0.0193 and 0.0271) tumors as well as in triple-negative and hormone-receptor negative/HER2-positive subtypes (p = 0.0310, 0.0280 and 0.0186). Ki and MRFDG were significantly higher in estrogen-receptor negative tumors (p = 0.0300 and 0.0247, respectively). Ki was significantly higher in node-positive than in node-negative disease (p = 0.0315). None of the assessed FDG-kinetic parameters showed significant correlation with stromal TIL. In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate. Furthermore, we found that kinetic parameters based on the dynamic examinations are probably not influenced by stromal TIL infiltration.

Indexed as

Breast NeoplasmsFemaleFluorodeoxyglucose F18HumansImage Interpretation, Computer-AssistedNeoplasm StagingPositron Emission Tomography Computed TomographyRadiopharmaceuticalsFluorodeoxyglucose F18RadiopharmaceuticalsBreast cancerKineticsPET-CTTumor-infiltrating lymphocytes

Identifiers

PMID30941738
PMCPMC7242263
OpenAlexW2926696132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.